Competing Interests: Disclosure Dr. Fan reports receiving honoraria from Heng Rui Therapeutics, AstraZeneca, Bristol-Myers Squibb, BeiGene, Pfizer, Boehringer Ingelheim, and Simcere; participated in a Data Safety Monitoring Board/advisory board for F. Hoffmann-La Roche Ltd. Dr. Drilon reports receiving honoraria from or participating in advisory boards for Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, AiCME, I3 Health, MonteRosa, InnoCare, and Boundless Bio; equity in Treeline Bio; associated research paid to institution from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, and PharmaMar; copyright to Selpercatinib-Osimertinib (filed/pending); research with Foundation Medicine; royalties from Wolters Kluwer; other (food/beverage) with Merck, Puma, Merus, and Boehringer Ingelheim, and CMS honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd, and Lungevity. Dr. Chiu reports receiving honoraria from Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, F. Hoffmann-La Roche Ltd, and Takeda; advisory/consultancy for Bristol-Myers Squibb, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, and F. Hoffmann-La Roche Ltd. Dr. Loong reports receiving funding from Novartis Pharmaceuticals, AbbVie, Bayer, Eisai, Eli Lilly, Guardant Health, Boehringer Ingelheim, Celgene, Illumina, Merck Sereno, Takeda, and George Clinical. Dr. Siena reports participation in advisory boards for Agenus, AstraZeneca, Bayer, Bristol-Myers Squibb, CheckmAb, Daiichi Sankyo, Guardant Health, Menarini, Merck, Novartis, F. Hoffmann-La Roche Ltd/Genentech, and Seattle Genetics. Dr. Krzakowski reports advisory/consultancy for Amgen, Boehringer Ingelheim, Janssen, and F. Hoffmann-La Roche Ltd. Dr. Dziadziuszko reports advisory/consultancy for F. Hoffmann-La Roche Ltd, Foundation Medicine, Pfizer, AstraZeneca, Novartis, Merck Sharp & Dohme, and Karyopharm; honoraria from F. Hoffmann-La Roche Ltd, AstraZeneca, and Amgen; and participation in Data Safety Monitoring Boards/advisory boards for F. Hoffmann-La Roche Ltd, AstraZeneca, Amgen, and Merck Sharp & Dohme. Mr. Zeuner and Ms. Xue are employees of F. Hoffman-La Roche Ltd. Dr. Krebs reports receiving honoraria from F. Hoffmann-La Roche Ltd; consulting/advisory fees from F. Hoffmann-La Roche Ltd, Guardant Health, Janssen, Seattle Genetics, OM Pharmaceutical Industries, and Bayer; speakers’ bureau for F. Hoffmann-La Roche Ltd, Janssen, and AstraZeneca; research funding from F. Hoffmann-La Roche Ltd, BerGenBio and Novartis; and travel/accommodation/expenses from AstraZeneca, BerGenBio, Immutep, and Janssen.